Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area
Stephanie Berg(Loyola University Medical Center), Santosh L. Saraf(University of Illinois Chicago), Erin M. Lowery(Loyola University Medical Center), Shuai Qin(Loyola University Medical Center), Saad Arain(University of Illinois Chicago), Katie W. Phelan(Loyola University Medical Center), Patrick J. Stiff(Loyola University Medical Center), Melissa L. Larson, Patrick Hagen(Loyola University Medical Center), Laura Pax(Loyola University Chicago), Candice Schwartz(Immunovaccine (Canada)), Nicholas Torgerson(Loyola University Medical Center), Hina Dalal(Loyola University Medical Center), Priya Rajakumar(Rush University Medical Center), Fatema Esmail(Loyola University Medical Center), Diana Kreppel(MacNeal Hospital), Tracie Watson(Loyola University Medical Center), Nasheed Hossain(Loyola University Chicago), Glenda Delgado-Ramos(Loyola University Medical Center), James Coggan(Rush University Medical Center), Elizabeth Elliott(Sydney Children’s Hospitals Network), Sonam Patel(Loyola University Medical Center), Oluwatobi Odetola(Northwestern University), Rebecca Feltman Frank(Loyola University Chicago), Amy Wozniak(Loyola University Chicago), Patrick Moore, Abhigna Kodali, Ellen Murchie(Harvard University), Daulath Singh(Loyola University Medical Center), Kevin Barton(Loyola University Medical Center), Ryan Guerrettaz(Loyola University Medical Center), Yanyu Zhang(Peking University), Seohyun Kim(Rush University Medical Center), Hanh Mai(Loyola University Medical Center), Anthi Katsouli(Loyola University Medical Center), Raymond W. Lee(MacNeal Hospital), Sucha Nand(Loyola University Medical Center), Ahmed Aleem(Loyola University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986